Pharmacology of the dual inhibitor of cyclooxygenase and 5-lipoxygenase 3-hydroxy-5-trifluoromethyl-N-(2-(2-thienyl)-2-phenyl-ethenyl)-benzo (b)thiophene-2-carboxamide.

Article

Author: Luell, S ; Bach, T ; Bailey, P J ; Anderson, R L ; Dallob, A L ; Meurer, R ; Allison, D L ; Durette, P L ; Hopple, S L ; Hand, K M

3-Hydroxy-5-trifluoromethyl-N-(2-(2-thienyl)-2-phenyl-ethenyl)- benzo (b) thiophene-2-carboxamide (L-652,343) is an inhibitor of cyclooxygenase and 5-lipoxygenase in vitro and inhibits the synthesis of the products of both these pathways in whole cells. L-652,343 is an inhibitor of the acute edema induced by carrageenan in vivo and is active topically in suppressing arachidonic acid induced inflammation in the skin. The compound is an effective inhibitor of the chronic inflammation of adjuvant and type II collagen induced polyarthritis. L-652,343 is an extremely potent analgesic in models of yeast and platelet activating factor induced hyperalgesia in rats and phenylbenzoquinone-induced writhing in mice. The fever induced by Brewer's yeast is lowered by L-652,343. The ulcerogenicity and gastric bleeding induced by L-652,343 is extremely low, providing a favorable therapeutic index which is superior to that of indomethacin, piroxicam and phenylbutazone.

01 Oct 1987·Biochemical PharmacologyQ2 · MEDICINE

L-652,343, a novel dual cyclo/lipoxygenase inhibitor, inhibits LTB4-production by stimulated human polymorphonuclear cells but not by stimulated human whole blood

Q2 · MEDICINE

Article

Author: Deckmyn, H. ; Arnout, J. ; Vermylen, J. ; Gresele, P.

L-652,343 (I) concentration-dependently inhibited LTB₄ formation by isolated, purified human polymorphonuclear leukocytes stimulated by A23187 (50% inhibitory concentration = 1.4 μM).However, I was inactive in A23187-stimulated whole blood (≤10^-3 M).The absence of activity appeared to be due to I binding to blood proteins.The loss of activity of blood was confined to the 5-lipopxygenase-inhibitory effect; in stimulated whole flood, I continued to inhibit TXB₂ formation, indicating persistence of blocking activity of platelet cyclooxygenase.

01 Jan 1986·Advances in prostaglandin, thromboxane, and leukotriene research

L-652,343: a novel dual 5-lipoxygenase/cyclooxygenase inhibitor.

Article

Author: Dougherty, H ; Dallob, A ; Allison, D ; Tischler, A ; Humes, J ; Durette, P ; Ham, E ; Rupprecht, K ; Bailey, P ; Witzel, B

100 Deals associated with L-652343

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Rheumatic Diseases	Phase 1	-	Merck Sharp & Dohme Corp.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

L-652343

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation